These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6092598)

  • 1. Solubility and complexation behavior of griseofulvin in fatty acid-isooctane mixtures.
    Mehdizadeh M; Grant DJ
    J Pharm Sci; 1984 Sep; 73(9):1195-203. PubMed ID: 6092598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylcholine-fatty acid membranes. I. Effects of protonation, salt concentration, temperature and chain-length on the colloidal and phase properties of mixed vesicles, bilayers and nonlamellar structures.
    Cevc G; Seddon JM; Hartung R; Eggert W
    Biochim Biophys Acta; 1988 May; 940(2):219-40. PubMed ID: 2835979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin.
    Dhanaraju MD; Kumaran KS; Baskaran T; Moorthy MS
    Drug Dev Ind Pharm; 1998 Jun; 24(6):583-7. PubMed ID: 9876628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short and medium chain fatty acids on absorption of lipophilic drugs from perfused rat intestine.
    Grisafe JA; Hayton WL
    J Pharm Sci; 1978 Sep; 67(9):1211-5. PubMed ID: 690822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the solubility characteristics of griseofulvin with gamma-cyclodextrin.
    Kata M; Tüske B
    Pharmazie; 1988 Jan; 43(1):52-3. PubMed ID: 3375309
    [No Abstract]   [Full Text] [Related]  

  • 6. Stacking complexation by nicotinamide: a useful way of enhancing drug solubility.
    Sanghvi R; Evans D; Yalkowsky SH
    Int J Pharm; 2007 May; 336(1):35-41. PubMed ID: 17145146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solubility limits and phase diagrams for fatty acids in anionic (SLES) and zwitterionic (CAPB) micellar surfactant solutions.
    Tzocheva SS; Kralchevsky PA; Danov KD; Georgieva GS; Post AJ; Ananthapadmanabhan KP
    J Colloid Interface Sci; 2012 Mar; 369(1):274-86. PubMed ID: 22212739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution rate of griseofulvin in bile salt solutions.
    de Smidt JH; Offringa JC; Crommelin DJ
    J Pharm Sci; 1991 Apr; 80(4):399-401. PubMed ID: 1865343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sodium dodecyl sulphate on the dissolution of poorly soluble drug into biorelevant medium from drug-surfactant discs.
    Madelung P; Ostergaard J; Bertelsen P; Jørgensen EV; Jacobsen J; Müllertz A
    Int J Pharm; 2014 Jun; 467(1-2):1-8. PubMed ID: 24594297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cosolvency approach for assessing the solubility of drugs in poly(vinylpyrrolidone).
    Chen X; Fadda HM; Aburub A; Mishra D; Pinal R
    Int J Pharm; 2015 Oct; 494(1):346-56. PubMed ID: 26272850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanistic study of griseofulvin dissolution into surfactant solutions under laminar flow conditions.
    Rao VM; Lin M; Larive CK; Southard MZ
    J Pharm Sci; 1997 Oct; 86(10):1132-7. PubMed ID: 9344170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on griseofulvin-polyethylene glycol 6000 systems.
    Chiou WL
    J Pharm Sci; 1977 Jul; 66(7):989-91. PubMed ID: 886463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal absorption of griseofulvin from a triolein digestion mixture in rats.
    Grisafe JA; Hayton WL
    J Pharm Sci; 1978 Jul; 67(7):895-9. PubMed ID: 660503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heptakis(2,6-di-O-methyl)-beta-cyclodextrin complexation with the antitumor agent chlorambucil.
    Green AR; Guillory JK
    J Pharm Sci; 1989 May; 78(5):427-31. PubMed ID: 2746481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of ordered mixtures for improving the dissolution rate of low solubility compounds.
    Nyström C; Westerberg M
    J Pharm Pharmacol; 1986 Mar; 38(3):161-5. PubMed ID: 2871148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution kinetics of griseofulvin in mixed micellar solutions.
    de Smidt JH; Grit M; Crommelin DJ
    J Pharm Sci; 1994 Sep; 83(9):1209-12. PubMed ID: 7830232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complexation in formulation of parenteral solutions: solubilization of the cytotoxic agent hexamethylmelamine by complexation with gentisic acid species.
    Kreilgård B; Higuchi T; Repta AJ
    J Pharm Sci; 1975 Nov; 64(11):1850-5. PubMed ID: 483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fatty acid solvates of griseofulvin-desolvation data.
    Grant DJ; Abougela IK
    J Pharm Pharmacol; 1981 Sep; 33(9):619-20. PubMed ID: 6117652
    [No Abstract]   [Full Text] [Related]  

  • 19. Thermochemical analysis of the dissolution process of Griseofulvin.
    Knoblauch J; Zimmermann I
    Eur J Pharm Biopharm; 2007 Nov; 67(3):743-51. PubMed ID: 17540547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acids for controlled release applications: A comparison between prilling and solid lipid extrusion as manufacturing techniques.
    Vervaeck A; Monteyne T; Siepmann F; Boone MN; Van Hoorebeke L; De Beer T; Siepmann J; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):173-84. PubMed ID: 26428938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.